Blog (insights)

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Making lung toxicity predictive, not reactive

This session highlighted where prediction fails today, the mechanistic gaps that limit current approaches, and how human NAMs can help close that gap. It also emphasised the key insights teams need to move from reactive findings to more proactive, informed decision-making.

De-risking nasal & pulmonary formulation development

To deliver therapeutics effectively to the nasal and pulmonary regions, developers must address the physiological barriers in these tissues. This webinar covers how formulation techniques and early in vitro toxicology work together to accelerate development and reduce risk.

Understanding off-target ADC lung toxicity: why human-relevant models matter

In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.

Looking beyond the baseline: new frontiers in lung and immune safety

In ImmuBYTES Session 3, “Looking Beyond Baseline Deviations for Lung and Immune Safety,” Prof. Victoria Hutter (CSO & Co-founder) highlighted how subtle changes in macrophage morphology can uncover early immune and lung effects.

Early detection of pulmonary ADC toxicity with high-content imaging of alveolar macrophages

Early detection of pulmonary ADC toxicity using ImmuONE’s morph_ONE™ high-content imaging assay of alveolar macrophages to improve safety and efficacy in ADC drug development.

Unlocking the power of immune cells: discover how they’re transforming inhalation toxicology

Immune cells are reshaping inhalation toxicology by offering deeper insights into respiratory and systemic effects of tested compounds. In the second ImmuBYTES webinar, ‘Immune cells as predictive tool for toxicology’, Dr. Ewelina Hoffman highlighted the crucial role of alveolar macrophages in improving preclinical safety assessments. Key highlights include: 1. Immune cells & alveolar macrophages As […]

ImmuONE raises £600K in investment for ‘3D lung’ to replace animal testing

A UK biotech start-up with a 3D human lung model that provides an alternative to animal testing has raised a further £600,000 from the Midlands Engine Investment Fund, Mercia Ventures and Pioneer Group. ImmuONE’s laboratory model is used to test new drugs, chemicals or consumer products to provide evidence they are safe to use. The […]

ImmuBYTES: a series of short webinars

Welcome to ImmuBYTES, a new series designed to deliver bite-sized insights into cutting-edge tools in cell-based research and toxicology to drive innovation and discovery.

Unveiling the Art of Image Analysis with Cell Painting

In our recent ImmuBYTES webinar, we delved into the fascinating world of Cell Painting, a high-content imaging assay (HCIA) that transforms cellular morphology into a rich source of data.

Celebrating Triple Triumph at the Inspiring Herts Awards 2024

Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.

Advancing Lung Toxicology: The Future of High Content Image Analysis

Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.

Our Scientific Lead in Genetic Toxicology, meet Dr Verma!

Dr. Verma joins us for a coffee to share his diverse journey from studying human and medical genetics to his groundbreaking work in genetic toxicology. Discover what drives Dr. Verma’s dedication to developing new genetic toxicity testing at ImmuONE.